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Abstract 
Purpose: Veno-arterial extracorporeal life support (ECLS) is increasingly used in patients during cardiac arrest and 
cardiogenic shock, to support both cardiac and pulmonary function. We performed a systematic review and meta-
analysis of cohort studies comparing mortality in patients treated with and without ECLS support in the setting of 
refractory cardiac arrest and cardiogenic shock complicating acute myocardial infarction.
Methods: We systematically searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials and 
the publisher subset of PubMed updated to December 2015. Thirteen studies were included of which nine included 
cardiac arrest patients (n = 3098) and four included patients with cardiogenic shock after acute myocardial infarction 
(n = 235). Data were pooled by a Mantel-Haenzel random effects model and heterogeneity was examined by the I2 
statistic.
Results: In cardiac arrest, the use of ECLS was associated with an absolute increase of 30 days survival of 13 % com-
pared with patients in which ECLS was not used [95 % CI 6–20 %; p < 0.001; number needed to treat (NNT) 7.7] and a 
higher rate of favourable neurological outcome at 30 days (absolute risk difference 14 %; 95 % CI 7–20 %; p < 0.0001; 
NNT 7.1). Propensity matched analysis, including 5 studies and 438 patients (219 in both groups), showed similar 
results. In cardiogenic shock, ECLS showed a 33 % higher 30-day survival compared with IABP (95 % CI, 14–52 %; 
p < 0.001; NNT 13) but no difference when compared with TandemHeart/Impella (−3 %; 95 % CI −21 to 14 %; 
p = 0.70; NNH 33).
Conclusions: In cardiac arrest, the use of ECLS was associated with an increased survival rate as well as an increase 
in favourable neurological outcome. In the setting of cardiogenic shock there was an increased survival with ECLS 
compared with IABP.
Keywords: Extracorporeal membrane oxygenation, Extracorporeal life support, Acute myocardial infarction, Cardiac 
arrest, Cardiogenic shock, Cardiopulmonary resuscitation, Systematic review
Introduction
Veno-arterial extracorporeal life support (ECLS), also 
called extracorporeal membrane oxygenation (ECMO), 
is a modified form of cardiopulmonary bypass to support 
both cardiac and pulmonary function. Technological 
improvements and miniaturisation have made this tech-
nique more accessible and its use has increased over the 
past years, especially in patients with refractory cardio-
genic shock or circulatory arrest [1, 2].
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Cardiogenic shock (CS) remains the leading cause of 
death in patients hospitalised for ST-segment elevation 
myocardial infarction (STEMI), as it may lead to multi-
organ failure due to insufficient organ perfusion [3, 4]. In 
addition to pharmacological measures, treatment with 
mechanical circulatory support can be considered, espe-
cially in more severe forms of circulatory failure.
The aim of mechanical circulatory support in general 
is to support the failing heart and the overall circula-
tion. Ideally, mechanical support is used as a bridge to 
either recovery or to other therapies such as a surgi-
cally implanted ventricular assist device (LVAD) or heart 
transplantation. It can be used in cardiogenic shock to 
prevent the development of multi-organ failure. In car-
diac arrest patients, mechanical circulatory support ena-
bles treatment of the underlying cause while maintaining 
adequate perfusion.
A multitude of mechanical support devices have been 
developed over the past decades and this field is attract-
ing increasing attention, especially after clinical trials did 
not show any clinical benefit for the intra-aortic balloon 
pump (IABP). Current European guidelines on cardio-
genic shock no longer support routine IABP therapy, 
whereas short-term mechanical circulatory support 
holds a class IIb recommendation [5, 6].
Percutaneous cannulation techniques facilitate rapid 
insertion and initiation of ECLS therapy in emergency 
situations, such as cardiac arrest. Although ECLS usage 
has increased and several observational studies suggest 
that it has had a beneficial effect in both cardiac arrest 
and cardiogenic shock, no randomised controlled trials 
have been performed to date. Therefore, the actual evi-
dence for its efficacy remains limited.
The main purpose of our study was to conduct a sys-
tematic review and meta-analysis of the available litera-
ture comparing ECLS with conventional therapy with 
regard to survival and neurological outcome in patients 
with cardiogenic shock after acute myocardial infarction 
(AMI) and patients with refractory cardiac arrest.
Methods
Selection criteria
Studies were considered for inclusion if they described 
outcome data from (A) patients with ECLS support and 
(B) a control group without ECLS support. Also, to qual-
ify for inclusion, patients must have been diagnosed with 
either (1) refractory in-hospital or out-of-hospital cardiac 
arrest or (2) cardiogenic shock after AMI. Studies that 
did not report on survival to discharge, 30-day outcome 
or 6-month outcome were excluded. This meta-analysis 
was conducted in accordance with the Preferred Report-
ing Items for Systematic Reviews and Meta-Analysis 
(PRISMA) guidelines [7].
Search strategy
A medical librarian (J.L.) conducted a systematic search 
of OVID MEDLINE, OVID EMBASE, the Cochrane 
Central Register of Controlled Trials (CENTRAL) and 
the publisher subset of PubMed from inception to 7 
December 2015. The search strategy consisted of con-
trolled vocabulary (i.e. MeSH) and free text words for 
two basic concepts: (1) ECLS and (2) cardiogenic shock, 
cardiac arrest or myocardial infarction (see Appendix 1 
in the electronic supplementary material for the entire 
MEDLINE search). Non-human studies, paediatric stud-
ies, case reports and reviews were excluded by double 
negation (NOT animals/NOT humans/) and/or exclud-
ing words in the title. We cross-checked the reference 
lists and the cited articles of the identified relevant papers 
for additional references. The bibliographic records 
retrieved were downloaded, imported and de-duplicated 
in ENDNOTE.
Data extraction and quality assessment
The retrieved articles were screened for relevance on 
title and abstract, followed by full-text screening by two 
independent investigators (D.O. and J.S.). In the event of 
overlapping patient cohorts the study with the longest 
follow-up period was included.
The prespecified patient and outcome data were inde-
pendently extracted by two investigators (D.O. and J.S.). 
Differences between reviewers regarding study selection 
or data extraction were resolved by consensus. The qual-
ity of the studies was assessed using a modified version 
of the Newcastle-Ottawa Quality Assessment Scale for 
Cohort Studies [8].
Data analysis
The primary endpoint was 30-day survival. Second-
ary outcomes were long-term survival and 30-day and 
long-term favourable neurological outcome. Parameters 
describing the clinical course and complications were 
extracted, e.g. successful weaning from the cardiac assist 
device, bridging to destination therapy (long-term ven-
tricular assist device or heart transplantation), timing of 
device placement, the occurrence of renal failure, stroke, 
peripheral vessel access complications and the need for 
blood transfusions (erythrocyte and fresh frozen plasma). 
If 30-day outcome data were not reported, in-hospital 
outcome data were used. For long-term data, the long-
est available follow-up was used. Neurological status 
was considered favourable when reported as either Pitts-
burgh Cerebral Performance Category (CPC) 1 or 2, or 
Modified Glasgow Outcome Score (MGOS) ≥4. Studies 
were grouped and presented by patient category: cardiac 
arrest or cardiogenic shock. A subcategory of propensity-
matched studies is reported separately. Propensity score 
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matching is a method used to balance observed covari-
ates in the two treatment arms by matching the propen-
sity score which represents the probability of receiving 
ECLS therapy.
Results are presented as absolute risk differences with 
a 95  % confidence interval (CI) and a number needed 
to treat (NNT) or number needed to harm (NNH) and 
were combined by a Mantel-Haenzel random effects 
model. Heterogeneity across studies was examined by 
the I2 statistic. Potential publication bias was assessed by 
visual assessment of constructed funnel plots. Tests were 
two-tailed and a p value of less than 0.05 was considered 
statistically significant. An I2 of greater than 40  % was 
considered to be an indication of substantial heterogene-




The de-duplicated results yielded a total of 1403 
abstracts. A total of 59 relevant articles were identified 
and the full-text article was independently reviewed. 
Figure 1 shows a flowchart for selection of studies. One 
article was excluded as the intervention group contained 
both ECLS and IABP patients [9]. Fourteen articles were 
identified.  Ten articles consisted of patients in refractory 
cardiac arrest [10–19]. However, two articles described 
the same cohort but with additional analysis [17 (Shin 
2013 Int J Card) ] [19 (Shin 2011 Crit Car Med]. This 
resulted in a total of 9 included cardiac arrest cohorts 
with a total of 3098 patients (708 ECLS versus 2390 con-
trol patients) (Table 1). Five of the cardiac arrest studies 
reported a propensity-matched analysis, including a total 
of 438 patients (219 in both groups) [10, 11, 13, 15, 19]. 
Four studies consisted of patients with cardiogenic shock 
with a total of 235 patients (151 ECLS versus 84 control 
patients) [20–23] (Table 1). 
Quality of studies
As all studies were cohort studies and no randomised 
controlled trials were available, the quality of the studies 
was low with a high risk of bias (Appendix 2). However, 
funnel plots did not show skewed distributions, suggest-
ing that no publication bias was involved (Appendix 3).
Cardiac arrest
Patient characteristics
Table 2 shows the baseline characteristics of the studies 
on ECLS in the setting of cardiac arrest. A total of nine 
studies were included with 3098 patients in total, 708 
in the ECLS group and 2390 in the control group. All 
studies included cardiac arrest patients, although with 
different inclusion criteria such as in-hospital cardiac 
arrest (IHCA), out-of-hospital cardiac arrest (OHCA), 
witnessed or non-witnessed cardiac arrest and differing 
durations of cardiopulmonary resuscitation (CPR). Over-
all, ECLS patients were more likely to be younger, male, 
suffer from acute myocardial infarction and to undergo 
primary PCI.
Survival
Figure 2a shows 30-day survival of patients with refrac-
tory cardiac arrest. The usage of ECLS in this setting was 
associated with increased survival at 30  days (absolute 
risk difference 13 %; 95 % CI 6–20 %; p < 0.001; NNT 7.7). 
The long-term difference in survival was 15 % in favour 
of the ECLS treated patients (see supplementary file) 
(absolute difference 15 %; 95 % CI 11–20 %; p < 0.0001; 
NNT 6.7). Short-term outcome data displayed substan-
tial heterogeneity (I2 = 64 %), but long-term survival did 
not (I2 = 28 %).
Neurological outcomes
Favourable neurological outcomes, defined as CPC 
score 1 or 2, are shown in Fig. 2b. The use of ECLS was 
associated with a higher rate of favourable neurological 
outcome at both 30  days (risk difference 14  %; 95  % CI 
7–20 %; p < 0.0001; NNT 7.1) and during long-term fol-
low-up (risk difference 11 %; 95 % CI 6–16 %; p < 0.0001; 
NNT 9.1) (supplementary data). Short-term outcome 
data were moderately heterogeneous (I2 = 52 %) but the 
long-term survival data did not show substantial hetero-
geneity (I2 = 28 %).
Other outcomes
Peripheral vessel complications were only reported by 
two studies. Blumenstein reported 17.3 % of patients with 
leg ischaemia or malperfusion in the ECLS arm and 2.9 % 
in the control arm. Maekawa et al. reported 7.7 % cannu-
lation site infection, 15.4 % leg ischaemia requiring rep-
erfusion and 2.9 % compartment syndrome in the ECLS 
patient group (supplementary data) [15]. Complication 
rates were very poorly reported. Only one of the cardiac 
arrest studies reported on renal failure (1.9 % in the ECLS 
patients versus 7  % in the control patients) [10]. Stroke 
and blood transfusions were not reported.
Propensity score matching
Five studies performed a propensity-matched analysis to 
balance observed covariates in the two treatment groups. 
The propensity score reflects the probability of receiv-
ing ECLS therapy. The baseline characteristics, after 
matching based on propensity score, can be seen in the 
supplementary data. The included patient population dif-
fered between studies in terms of location of the arrest 
(IHCA versus OHCA), witnessed or unwitnessed arrest, 
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presumed cardiac origin and duration of CPR. After pro-
pensity matching, the patients treated with ECLS and 
control patients were comparable in terms of age and 
gender. There were more patients in the ECLS arm than 
in the control arm receiving primary PCI, as only one of 
the five propensity-matched studies included primary 
Fig. 1 Flowchart of the search strategy and selection of studies. Asterisk: 1 article reported on the same patient cohort as another included article, 
but provided additional data on propensity-matched analysis and was therefore included
Table 1 Summary of included cohort studies on cardiogenic shock and cardiac arrest patients
a Not defined, median long-term follow-up was 1136 (823–1415) days
References Country Study period Setting Follow-up duration Number of patients
Cardiac arrest
 Blumenstein et al. [10] Germany 2009–2013 Retrospective, single centre Long terma 353
 Chen et al. [11] Taiwan 2004–2006 Prospective, single centre 1 year 172
 Chou et al. [12] Taiwan 2006–2010 Retrospective, single centre 1 year 66
 Kim et al. [13] Korea 2006–2013 Prospective, single centre 3 months 499
 Lee et al. [14] Korea 2009–2014 Retrospective, single centre In-hospital 955
 Maekawa et al. [15] Japan 2000–2004 Prospective, single centre 3 months 162
 Sakamoto et al. [16] Japan 2008–2011 Prospective, multi-centre 6 months 454
 Shin et al. [17] Korea 2003–2009 Retrospective, single centre 2 years 406
 Siao et al. [18] Taiwan 2011–2013 Retrospective, single centre 1 year 60
Cardiogenic shock
 Chamogeorgakis et al. [20] USA 2006–2011 Retrospective, single centre In-hospital 79
 Lamarche et al. [21] Canada 2000–2009 Retrospective, single centre 30 days 61
 Sattler et al. [22] Germany 2011–2012, 2012–2013 Retrospective, single centre 30 days 24
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PCI as a matching variable. The use of ECLS was asso-
ciated with a higher survival rate at 30  days (difference 
14  %; 95  % CI 2–25  %; p  =  0.02; NNT 7.1) and in the 
long-term (difference 13 %; 95 % CI 6–20 %; p = 0.001; 
NNT 7.7) (Fig.  2c and supplementary data). Also, the 
use of ECLS was associated with a higher rate of favour-
able neurological outcome at both 30  days (risk differ-
ence 13  %; 95  % CI 7–20  %; p =  0.0001; NNT 7.7) and 
in the long-term (risk difference 14 %; 95 % CI 8–20 %; 
p < 0.0001; NNT 7.1) (Fig. 2d and supplementary data). 
In the propensity-matched analysis, short-term survival 
showed substantial heterogeneity (I2 =  54  %), but long-




Table 3 shows the baseline characteristics of the studies 
on ECLS in cardiogenic shock patients. A total of four 
studies were included with 235 patients in total, 151 in 
the ECLS group and 84 in the control group. All stud-
ies included cardiogenic shock patients after myocardial 
infarction, albeit with different inclusion criteria such 
as refractory CS, progressive CS or decompensated car-
diomyopathy. In two studies, the control arm consisted of 
IABP support, and in two other studies, the control arm 
consisted of patients supported by Impella 5.0, Impella 
RD or TandemHeart. Patients in the ECLS arm were gen-
erally younger and were less likely to suffer from acute 
myocardial infarction (Table  3). In the two studies with 
IABP support in the control group, all patients were diag-
nosed with STEMI and treated with primary PCI.
Survival outcomes
Figure 3 shows the absolute number of survivors among 
patients with and without ECLS treatment, with the 
absolute risk difference for each study, stratified by the 
different control arms. The studies with IABP in the 
control arm showed that ECLS support in the setting of 
cardiogenic shock was associated with improved 30-day 
survival (risk difference 33  %; 95  % CI 14–52  %; p = 
0.0008; NNT 3). When ECLS was compared with Impella 
or TandemHeart, ECLS was not associated with a signifi-
cant difference in 30-day survival (risk difference −3 %; 
95  % CI −21 to 14  %; p =  0.70; NNH 33). When com-
bining the control groups (IABP and Impella/Tandem-
Heart), the use of ECLS was not associated with a change 
in 30-day survival in patients with cardiogenic shock (risk 
difference 14 %, 95 % CI -8-35 %; p = 0.20; NNT 7.1). The 
analysis stratified according to control arm did not show 
any heterogeneity (I2 = 0 %), but the overall effects were 
substantially heterogeneous (I2  =  60  %). The long-term 
survival and neurological outcomes were not described 
in these studies.
Fig. 2 Risk difference of 30-day survival (a) and favourable neurologic outcome (CPC 1 or 2) (b) and propensity-matched risk difference in 30-day 















































































































































































































































































































































































































































































































































































































































































































































































































































































The percentage of patients who were successfully weaned 
from ECLS and the percentage of patients who were 
bridged to long-term ventricular assist device or heart 
transplant are shown in the supplementary data. Only 
Sattler et  al. reported the time of device placement: in 
one patient, ECLS was placed before PCI, in nine patients 
immediately after PCI and in two patients ECLS therapy 
was initiated within 24–48  h after PCI with IABP sup-
port. Peripheral vessel complications and blood trans-
fusions are shown in the supplementary data. Only one 
study reported the incidence of renal failure, with renal 
failure occurring in 58.3 % of patients treated with ECLS 
and in 25.0 % of the control patients [22]. Stroke was not 
reported by any study.
Discussion
We conducted two meta-analyses of cohort studies com-
paring ECLS therapy with varying control groups in the 
settings of cardiac arrest and cardiogenic shock. In the 
setting of cardiac arrest, the usage of ECLS showed an 
increase in survival of 13  % and an increase of favour-
able neurological outcome of 14 % at 30-days compared 
with no usage of ECLS. This effect was still prominent 
after baseline characteristics were adjusted by propensity 
matching. In patients with cardiogenic shock, ECLS was 
associated with higher 30-day survival compared with 
IABP, but there was no difference in survival when com-
pared with Impella or TandemHeart.
In the absence of randomised controlled trials, we 
included non-randomised studies and therefore cannot 
rule out the influence of confounders. As a result, there 
was a difference in baseline characteristics between ECLS 
and control patients. ECLS-treated patients were more 
likely to be male, younger, suffer from acute myocar-
dial infarction and were more likely to undergo primary 
PCI—all factors known to be associated with increased 
survival in this setting [24–26]. Another potentially 
important bias towards poor outcomes in the ‘control/no-
ECLS’ group may be due to the fact that sicker patients 
may have been considered too ill to benefit from ECLS 
therapy and others may have died before they could 
receive ECLS therapy. As it is difficult to reliably distin-
guish between the effect of ECLS therapy and the effect of 
the bias and confounding inherent to cohort studies, the 
results of this analysis should be interpreted with caution. 
Nevertheless, the propensity-matched analysis in cardiac 
arrest, with matching baseline characteristics, showed 
results comparable with the outcome of the cohort 
studies.
In addition to the difference in baseline characteristics 
of the patients, differences in the treatment of patients 
might have influenced the results. Patients with cardiac 
arrest treated with ECLS were more likely to be revascu-
larised. This finding suggests that the use of ECLS allows 
for more frequent revascularisation. Kagawa et al. inves-
tigated the effectiveness of intra-arrest PCI during ECLS, 
and they reported a higher survival rate in the intra-
arrest PCI groups compared with delayed PCI (36 versus 
12 %) [27]. The fact that ECLS-assisted CPR allowed for 
timely treatment of the underlying cause, such as intra-
arrest PCI, might partly explain the increased survival in 
ECLS-assisted CPR.
In the cardiogenic shock patients, the difference in 
treatment effect may be explained by the amount of 
haemodynamic support that is generated by the mechan-
ical support device. The used Impella devices (5.0 and 
RP) and TandemHeart actively support the circulation 
with around 4  L/min, which is comparable to ECLS, 
whereas the IABP only passively supports the overall 
circulation with ca. 0.5  L/min. However, a small meta-
analysis of randomised trials comparing IABP (n =  47) 
Fig. 3 Difference of 30-day survival of patients with cardiogenic shock, stratified according to different control therapies (IABP or Impella/Tandem-
Heart)
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with Impella/TandemHeart (n = 53) in CS complicating 
AMI did not show any difference in outcome [28]. This 
seems to contradict the previous hypothesis that ECLS, 
TandemHeart and Impella 5.0 might all be superior to 
IABP as they provide more haemodynamic support. This 
apparent contradiction may be explained by the differ-
ent characteristics of the patients included, the differ-
ences in definition of (profound) CS and the low number 
of patients included in both meta-analyses. Although the 
support level of the used devices may be similar (around 
4 L/min), they have different specifications and therefore 
different clinical indications [4, 5].
The variety of inclusion criteria in the included stud-
ies is likely to have contributed to the heterogene-
ity. Although we aimed to include patients with acute 
myocardial infarction, some cardiogenic shock studies 
included patients with a wide variety of aetiologies (100 % 
AMI in the IABP studies, but lower in the Impella/Tan-
demheart studies (no exact number reported)). In the 
cardiac arrest studies, there was variation in the location 
of the arrest, duration of no-flow and CPR. The inclusion 
criteria resulted in relatively low no-flow times as most 
studies included IHCA arrest, witnessed OHCA with 
bystander CPR, or mandatory low no-flow times. It is not 
known whether shorter no-flow and CPR duration before 
deploying ECLS results in a better outcome compared 
with conventional CPR. However, survival and outcome 
deteriorate as duration of no-flow and CPR increases [11].
Although vascular and bleeding complications are 
known to occur frequently during ECLS therapy, only 
a few of the included studies reported on these compli-
cations. Two previously published pooled analyses of 
complications of ECLS both reported high complication 
rates [29, 30]. They did not compare those rates with 
non-ECLS-treated patients. In these pooled analyses, 
lower limb ischaemia occurred in 16.9 and 10.7 %, which 
is comparable with our range of peripheral vessel com-
plications, which is between 8.7 and 25  %. The occur-
rence of events may be directly related to ECLS therapy, 
or indirectly to the critical conditions of patients treated 
with ECLS. Either way we must keep in mind that sur-
vival with good neurological outcome might outweigh 
the risk for complications. In addition, complications 
during ECLS can only occur when patients are still alive 
for complications to occur. Therefore, the value of com-
plications in these extremely high-risk patients is a rela-
tive one. The current meta-analysis found a survival rate 
of 45.2 % in cardiogenic shock patients and 27.4 % in the 
cardiac arrest patients treated with ECLS. These numbers 
are consistent with data from Xie et al., who performed a 
pooled analysis of observational cohort studies (without 
control arm) on patients treated with ECLS for refrac-
tory cardiogenic shock (n  =  659) or for cardiac arrest 
(n = 277), and demonstrated a 30-day survival of 52.5 % 
in CS and 36.2 % in cardiac arrest [31].
Currently, ECLS has a class IIb recommendation (may 
be considered) in the European and American guidelines 
on myocardial revascularisation [6, 32]. The European 
Resuscitation Council (ERC) guidelines recommend that 
ECLS-assisted CPR should be considered to facilitate 
interventions [33]. Although the guidelines recommend 
consideration of ECLS, ECLS requires multidisciplinary 
expertise, which is often only available in a limited number 
of specialised centres. Experience is gained by providing 
ECLS support in remote locations and in the prehospital 
field to allow transfer to an experienced ECLS centre [27, 
34–36]. In addition, the high cost of ECLS is a limiting fac-
tor, which mandates appropriate case selection.
Although the findings of this meta-analysis were lim-
ited by the heterogeneity of included studies, in the 
absence of large randomised trials, this pooled analysis 
represents the best available method for evaluating ECLS. 
These data should be taken into account when updating 
the clinical guidelines on cardiac arrest. Ultimately, to 
clarify the role of ECLS in cardiogenic shock and cardiac 
arrest, a randomised controlled trial should be under-
taken; however, many randomised trials in this patient 
category have been aborted as a result to low inclusion 
rates [37]. Therefore, while aiming for a randomised trial, 
large multicentre registries could be the first step towards 
identifying patients that may benefit from ECLS or other 
circulatory support devices.
In conclusion, the current meta-analysis aggregated all 
available evidence on the effectiveness of ECLS in the con-
tinuous field of cardiac failure, ranging from cardiogenic 
shock to cardiac arrest. In the setting of refractory cardiac 
arrest, the meta-analysis showed increased survival and 
favourable neurological outcomes in the ECLS-treated 
patients. In the setting of cardiogenic shock there was an 
increased survival with ECLS compared with IABP.
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